A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines

被引：40

作者：

Peruzzi, Daniela ^{[1
]}

Dharmapuri, Sridhar ^{[1
]}

Cirillo, Agostino ^{[1
]}

Bruni, Bruno Ercole ^{[1
]}

Nicosia, Alfredo ^{[2
]}

Cortese, Riccardo ^{[2
]}

Colloca, Stefano ^{[2
]}

Ciliberto, Gennaro ^{[1
]}

La Monica, Nicola ^{[1
]}

Aurisicchio, Luigi ^{[1
]}

机构：

[1] IRBM, Merck Res Labs, Oncol Funct Dept, I-00040 Rome, Italy

[2] Okairos, I-00040 Rome, Italy

来源：

VACCINE | 2009年 / 27卷 / 09期

关键词：

Adenovirus; Vaccination; Tumor immunity; T-CELL RESPONSE; CARCINOEMBRYONIC ANTIGEN; RECOMBINANT ADENOVIRUS; IMMUNE-RESPONSE; NONHUMAN-PRIMATES; NEUTRALIZING ANTIBODIES; ANTI-AD5; IMMUNITY; TRANSGENIC MICE; RHESUS-MONKEYS; GENE-TRANSFER;

D O I：

10.1016/j.vaccine.2008.12.051

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The use of adenovirus (Ad) as vaccine vectors is hindered by pre-existing immunity to human Ads in most of the human population. In order to overcome this limitation, uncommon alternative Ad serotypes need to be utilized, In this study, an E1-E3 deleted recombinant Ad based on the chimpanzee serotype 3 (ChAd3) was engineered to express human carcinoembryonic antigen (CEA) protein or rat neu extracellular/transmembrane domains (ECD.TM). ChAd3 vectors were tested in CEA transgenic (CEA.Tg) and BALB/NeuT mice, which show immunologic tolerance to these antigens. ChAd3 is capable of inducing an immune response comparable to that of hAd5 serotype-based vectors, thus breaking tolerance to tumor associated antigens (TAAs) and achieving anti-tumor effects. Of importance is that ChAd3 can overcome hAd5 pre-existing immunity and work in conjunction with DNA electroporation (DNA-EP) and other Ad vaccines based on common human serotypes. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：1293 / 1300

页数：8

共 63 条

[1] Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene:: Application in epidemiologic studies and in the design of adenovector vaccines [J].

Aste-Amézaga, M ;

Bett, AJ ;

Wang, FB ;

Casimiro, DR ;

Antonello, JM ;

Patel, DK ;

Dell, EC ;

Franlin, LL ;

Dougherty, NM ;

Bennett, PS ;

Perry, HC ;

Davies, ME ;

Shiver, JW ;

Keller, PM ;

Yeager, MD .

HUMAN GENE THERAPY, 2004, 15 (03) :293-304

[2] Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates [J].

Aurisicchio, Luigi ;

Mennuni, Carmela ;

Giannetti, Patrizia ;

Calvaruso, Francesco ;

Nuzzo, Maurizio ;

Cipriani, Barbara ;

Palombo, Fabio ;

Monaci, Paolo ;

Ciliberto, Gennaro ;

La Monica, Nicola .

INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (11) :2290-2300

[3] The influence of blood on in vivo adenovirus bio-distribution and transduction [J].

Baker, Andrew H. ;

Mcvey, John H. ;

Waddington, Simon N. ;

Di Paolo, Nelson C. ;

Shayakhmetov, Dmitry M. .

MOLECULAR THERAPY, 2007, 15 (08) :1410-1416

[4] Development of nonhuman adenoviruses as vaccine vectors [J].

Bangari, DS ;

Mittal, SK .

VACCINE, 2006, 24 (07) :849-862

[5] Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture [J].

Bangari, DS ;

Mittal, SK .

VIRUS RESEARCH, 2004, 105 (02) :127-136

[6] Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].

Barouch, DH ;

Pau, MG ;

Custers, JHHV ;

Koudstaal, W ;

Kostense, S ;

Havenga, MJE ;

Truitt, DM ;

Sumida, SM ;

Kishko, MG ;

Arthur, JC ;

Korioth-Schmitz, B ;

Newberg, MH ;

Gorgone, DA ;

Lifton, MA ;

Panicali, DL ;

Nabel, GJ ;

Letvin, NL ;

Goudsmit, J .

JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297

[7] Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein [J].

Belousova, N ;

Krendelchtchikova, V ;

Curiel, DT ;

Krasnykh, V .

JOURNAL OF VIROLOGY, 2002, 76 (17) :8621-8631

[8] Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene [J].

Casimiro, DR ;

Chen, L ;

Fu, TM ;

Evans, RK ;

Caulfield, MJ ;

Davies, ME ;

Tang, A ;

Chen, MC ;

Huang, LY ;

Harris, V ;

Freed, DC ;

Wilson, KA ;

Dubey, S ;

Zhu, DM ;

Nawrocki, D ;

Mach, H ;

Troutman, R ;

Isopi, L ;

Williams, D ;

Hurni, W ;

Xu, Z ;

Smith, JG ;

Wang, S ;

Liu, X ;

Guan, LM ;

Long, R ;

Trigona, W ;

Heidecker, GJ ;

Perry, HC ;

Persaud, N ;

Toner, TJ ;

Su, Q ;

Liang, XP ;

Youil, R ;

Chastain, M ;

Bell, AJ ;

Volkin, DB ;

Emini, EA ;

Shiver, JW .

JOURNAL OF VIROLOGY, 2003, 77 (11) :6305-6313

[9] Therapeutic vaccination halts disease progression in BALB-neuT mice:: The amplitude of elicited immune response is predictive of vaccine efficacy [J].

Cipriani, Barbara ;

Fridman, Arthur ;

Bendtsen, Claus ;

Dharmapuri, Shridar ;

Mennuni, Carmela ;

Pak, Irene ;

Mesiti, Giuseppe ;

Forni, Guido ;

Monaci, Paolo ;

Bagchi, Ansu ;

Ciliberto, Gennaro ;

La Monica, Nicola ;

Scarselli, Elisa .

HUMAN GENE THERAPY, 2008, 19 (07) :670-680

[10] DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles [J].

Cox, Kara S. ;

Clair, James H. ;

Prokop, Michael T. ;

Sykes, Kara J. ;

Dubey, Sheri A. ;

Shiver, John W. ;

Robertson, Michael N. ;

Casimiro, Danilo R. .

JOURNAL OF VIROLOGY, 2008, 82 (16) :8161-8171

← 1 2 3 4 5 6 7 →